Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Interventional Pulmonology, Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Adv Respir Med. 2020;88(4):305-312. doi: 10.5603/ARM.a2020.0120.
There is an association between the activation of mammalian target of rapamycin (mTOR) signaling and aggressive tumor growth in multiple forms of cancer,including adenoid cystic carcinoma (ACC). ACCs are uncommon yet a malignant form of neoplasms that arises within the secretory glands. Therefore, the aim of this study was to investigate the increase of mTOR in the ACC tumors in order to survey the possibility of treating these tumors with mTOR inhibitors.
Samples from known cases of the lung and tracheal ACC were retrievedfrom the archives of the pa-thology department of Masih Daneshvari hospital, and immunohistochemical (IHC) staining for mTOR was performed on them. After preparation of the blocks with specific antibodies, tumor cells with cytoplasmic and/or nuclear expression of mTOR were considered as positive cells by applying a specific scoring method introduced in this study.
The paraffin blocks of 26 patients were surveyed and the IHC marker of mTOR was positive in the tumors of 10 patients (38.5%). Out of 10 mTOR positive cases, 5 were females and 5 were males. The primary site of the surveyed tumors was the trachea and bronchus in 12 cases (46%), salivary glands in 7 individuals (27%), and lung tissue in 7 cases (27%), and there was no significant correlation between the primary site of the ACC tumors and the existence of the mTOR markers in them (P = 0.67). From all cases, 13 patients (50%) had cribriform and tubular cells without solid components, 9 cases (34.6%) had cribriform and tubular with less than 30% of solid components, and 4 cases (15.4%) had cribriform and tubular cells with more than 30% of solid com-ponents. There was no significant difference between the morphologies and the existence of mTOR markers in them (P = 0.741).
As the incidence of mTOR markers is seen in patients with tracheal ACC, evaluation and scoring of mTOR in these persons can be helpful as further studies can distinguish the use of it in the treatment of the disease. .
哺乳动物雷帕霉素靶蛋白（mTOR）信号的激活与多种癌症包括腺样囊性癌（ACC）的侵袭性肿瘤生长有关。ACC 是一种罕见的恶性肿瘤，发生在分泌腺内。因此，本研究旨在探讨 ACC 肿瘤中 mTOR 的增加，以调查使用 mTOR 抑制剂治疗这些肿瘤的可能性。
从 Masih Daneshvari 医院病理科的档案中检索到已知的肺和气管 ACC 病例的样本，并对其进行 mTOR 免疫组织化学（IHC）染色。在使用本研究中引入的特定评分方法对肿瘤细胞进行细胞质和/或核 mTOR 表达阳性细胞的评估后，制备具有特定抗体的块。
调查了 26 例患者的石蜡块，10 例患者（38.5%）的 IHC 标志物 mTOR 阳性。在 10 例 mTOR 阳性病例中，女性 5 例，男性 5 例。被调查肿瘤的原发部位为气管和支气管 12 例（46%）、唾液腺 7 例（27%）和肺组织 7 例（27%），但 ACC 肿瘤的原发部位与其中 mTOR 标志物的存在之间无显著相关性（P=0.67）。所有病例中，13 例（50%）为无实性成分的筛状和管状细胞，9 例（34.6%）为有小于 30%实性成分的筛状和管状，4 例（15.4%）为有大于 30%实性成分的筛状和管状细胞。它们的形态和 mTOR 标志物的存在之间无显著差异（P=0.741）。
由于在气管 ACC 患者中可见 mTOR 标志物的发生率，因此对这些患者进行 mTOR 的评估和评分可能有助于进一步研究区分其在疾病治疗中的应用。
